Search results for "Allergists"

showing 6 items of 6 documents

Catching allergy by a simple questionnaire

2014

Background Identifying allergic rhinitis requires allergy testing, but the first-line referral for rhinitis are usually primary care physicians (PCP), who are not familiar with such tests. The availability of easy and simple tests to be used by PCP to suggest allergy should be very useful. Methods The Respiratory Allergy Prediction (RAP) test, based on 9 questions and previously validated by a panel of experts, was evaluated in this study. Results An overall number of 401 patients (48.6% males, age range 14–62 years) with respiratory symptoms was included. Of them, 89 (22.2%) showed negative results to SPT, while 312 (77.8%) had at least one positive result to SPT. Cohen’s kappa coefficient…

lcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAllergyReferralAllergymedicine.medical_treatmentImmunologyAllergy testingPrimary careAllergy testingSettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacistsAllergic rhinitisCohen's kappaAllergic rhinitimedicineImmunology and AllergyOriginal Researchbusiness.industrymedicine.diseaseAllergic rhinitis; Allergy; Allergy testing; Pharmacists; Primary care physicians; Immunology and AllergyTest (assessment)Primary care physicianNasal sprayPharmacistPrimary care physiciansAllergistslcsh:RC581-607business
researchProduct

Tropomyosin: A panallergen that causes a worldwide allergic problem

2021

Background: Panallergens are proteins that take part in key processes of organisms and, therefore, are ubiquitously distributed with highly conserved sequences and structures. One class of these panallergens is composed of the tropomyosins. The highly heat-stable tropomyosins comprise the major allergens in crustaceans and mollusks, which make them important food allergens in exposed populations. Tropomyosins are responsible for a widespread immunoglobulin E cross-reactivity among allergens from different sources. Allergic tropomyosins are expressed in many species, including parasites and insects. Methods: This panallergen class is divided, according to it capacity of induced allergic symp…

Pulmonary and Respiratory Medicineinsect allergymacromolecular substancesCross Reactionsmedicine.disease_causeImmunoglobulin EConserved sequencetropomyosinAllergenFood allergybiology.animalmedicineImmunology and AllergyHumansAmino Acid Sequenceseafood allergyGeneticsfood allergybiologybusiness.industryVertebrateGeneral MedicineArticlesAllergensImmunoglobulin Emedicine.diseasemusculoskeletal systemTropomyosinIgE cross-reactivitypanallergenAllergic responsebiology.proteinhouse-dust mite allergyAllergistsbusinesstissuesFood Hypersensitivity
researchProduct

A European survey of management approaches in chronic urticaria in children: EAACI Paediatric Urticaria Taskforce

2021

Background: Although well described in adults, there are scarce and heterogeneous data on the diagnosis and management of chronic urticaria (CU) in children (0-18 years) throughout Europe. Our aim was to explore country differences and identify the extent to which the EAACI/GA²LEN/EDF/WAO guideline recommendations for paediatric urticaria are implemented. Methods: The EAACI Taskforce for paediatric CU disseminated an online clinical survey among EAACI paediatric section members. Members were asked to answer 35 multiple choice questions on current practices in their respective centres. Results: The survey was sent to 2,773 physicians of whom 358 (13.8%) responded, mainly paediatric allergist…

Adultmedicine.medical_specialtyUrticariaImmunologyDermatologyOmalizumabOmalizumaburticaria diagnosischronic urticariaSecond lineSurveys and QuestionnairesHumansImmunology and AllergyMedicineChronic UrticariaChildChronic urticariachildurticaria treatmentbusiness.industryTask forceGuidelineThird lineFamily medicineChronic DiseasePediatrics Perinatology and Child HealthHistamine H1 AntagonistsomalizumabAllergistsApproaches of managementbusinessmedicine.drug
researchProduct

Adherence issues related to sublingual immunotherapy as perceived by allergists.

2010

Silvia Scurati1, Franco Frati1, Gianni Passalacqua2, Paola Puccinelli1, Cecile Hilaire1, Cristoforo Incorvaia3, Italian Study Group on SLIT Compliance 1Scientific and Medical Department, Stallergenes, Milan, Italy; 2Allergy and Respiratory Diseases, Department of Internal Medicine, Genoa; 3Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, ItalyObjectives: Sublingual immunotherapy (SLIT) is a viable alternative to subcutaneous immunotherapy to treat allergic rhinitis and asthma, and is widely used in clinical practice in many European countries. The clinical efficacy of SLIT has been established in a number of clinical trials and meta-analyses. However, because SLIT is self-administered…

medicine.medical_specialtyPathologygenetic structuresefficacyAlternative medicineMedicine (miscellaneous)Adherence Cost Efficacy Side effects Sublingual immunotherapySettore MED/10 - Malattie Dell'Apparato Respiratoriosublingual immunotherapyALLERGENcostmedicineSubcutaneous immunotherapySublingual immunotherapyadherenceClinical efficacyIntensive care medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)sublingual immunoterapyOriginal ResearchAsthmaAEROALLERGENSadherence; sublingual immunotherapy; efficacy; cost; side effectsbusiness.industryHealth Policymedicine.diseaseSliteye diseasesClinical trialside effectsPatient Preference and Adherenceadherence; sublingual immunoterapy; efficacy; cost; side effects.immunotherapysense organsAllergistsADHERENCE TO TREATMENTbusinessSocial Sciences (miscellaneous)
researchProduct

Mastocytosis - pathogenesis, clinical manifestation and treatment

2017

The term mastocytosis designates a group of rare disorders characterized by typical skin lesions, frequently associated episodes of anaphylaxis, and clinical symptoms related to the release of various mediators. Dermatologists/allergists are frequently the first to establish the diagnosis. The condition is based on clonal mast cell proliferation, usually in the skin or bone marrow and only rarely in the gastrointestinal tract or other tissues. In general, mastocytosis has a good prognosis in terms of life expectancy. Rare variants - including mast cell leukemia, aggressive mastocytosis, and the exceedingly rare mast cell sarcoma - require cytoreductive therapy. In cases associated with hema…

0301 basic medicinemedicine.medical_specialtyGastrointestinal tractbusiness.industryDermatologymedicine.diseaseMast cell leukemiaDermatologyMast cell proliferation03 medical and health sciences030104 developmental biologymedicine.anatomical_structuremedicineMast cell sarcomaHematological neoplasmAllergistsBone marrowbusinessAnaphylaxisJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Beliefs and preferences regarding biological treatments for severe asthma

2020

Background: Severe asthma is a serious condition with a significant burden on patients' morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and interleukin-5 (IL5) mediated pathways are now available. Due to the lack of direct comparison studies, the choice of which medication to use varies. We aimed to explore the beliefs and practices in the use of biological therapies in severe asthma, hypothesizing that differences will occur depending on the prescribers’ specialty and experience. Methods: We conducted an online survey composed of 35 questions in English. The survey was circulated via the INterasma Scientific Network (INESNET) platform as well as throu…

Severe asthmaBehavior; Belief; Biological drug; Severe asthmainterleukine 5 IgEMULTICENTERDiseaseOmalizumabADD-ON THERAPYBehavior Belief Biological drug Severe asthmaDOUBLE-BLIND0302 clinical medicineMedicine and Health SciencesImmunology and AllergyEosinophil IL5 [Eos]030223 otorhinolaryngologyPulmonologistssevere asthma biological drug belief behavior3. Good healthBeliefSAFETYmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyEos: Eosinophil IL5ImmunologyBiological drugSpecialtylong-acting beta2-agonist OMASocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioArticle03 medical and health sciencesQuality of life (healthcare)Omalizumab. OMA/IL5 Omalizumab plus anti-IL5 moleculeOMALIZUMABmedicineIntensive care medicineAsthmaBehaviorINterasma Scientific Network LABAbusiness.industryMEPOLIZUMABmedicine.diseaseEFFICACYICS inhaled corticosteroidsLIFE030228 respiratory systemImmunoglobulin E INESNETAllergistslcsh:RC581-607businessMepolizumab
researchProduct